Form 4: Balchem Director Rigaud Receives Restricted Stock Grant

Balchem Corporation Director Olivier Rigaud was granted 870 shares of restricted common stock, vesting one year from the grant date.

Summary

• Olivier Rigaud, a Director of Balchem Corporation (BCPC), acquired 870 shares of common stock.
• The transaction occurred on February 11, 2026, at a price of $0 per share, indicating a grant of restricted stock.
• Following this transaction, Rigaud beneficially owns 2,390 shares of common stock directly.
• The restricted stock vests one year after the grant date, subject to transfer restrictions outlined in the Restricted Stock Grant Agreement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as it signifies continued alignment of a director's interests with the company's long-term performance through equity compensation.

Positives

• The grant of restricted stock to Director Olivier Rigaud aligns his interests with long-term shareholder value.
• An increase in direct beneficial ownership by a director can signal confidence in the company's future prospects.

Risks

• The value of the restricted stock is subject to the future performance of Balchem Corporation's common stock.
• The shares are subject to transfer restrictions until vesting, meaning the director cannot immediately sell them.

Future Outlook

The restricted stock vests one year following the grant date, indicating a future milestone for the director's ownership.

Industry Context

StockSavvy.ai notes that restricted stock grants are a common form of equity compensation for directors and executives across various industries, designed to incentivize long-term commitment and align management interests with shareholder returns. This grant is consistent with typical corporate governance practices for public companies like Balchem.

Comparison to Industry Standards

• Restricted stock grants are a standard component of director compensation packages in U.S. public companies, comparable to practices at peers in the specialty chemicals and nutritional ingredients sectors such as Kerry Group plc or DSM-Firmenich AG, which also utilize equity-based incentives to retain and motivate key personnel.
• The $0 transaction price is typical for a stock grant, reflecting compensation rather than a market purchase.

Related Party Transactions

• The restricted stock grant to a director is a related party transaction, but it is a standard form of compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on general employees is indicated.

Next Steps

• The restricted stock will vest one year following the grant date of February 11, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine restricted stock grant to a director, which is a standard compensation practice and does not provide new material information that would significantly alter the investment thesis for Balchem Corporation. It indicates continued alignment of director interests with the company's long-term performance but does not warrant a change from a 'hold' position based solely on this disclosure.

Keywords

Balchem, BCPC, Form 4, Insider Trading, Restricted Stock, Stock Grant, Director Compensation, Equity Compensation, Olivier Rigaud